Akèy › Kansè poumon › Tennessee › Nashville
Etid klinik pou Kansè poumon nan Nashville, TN
40 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- SCRI Oncology Partners, Nashville
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Nashville
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- SCRI Oncology Partners - Tennessee, Nashville
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ap rekriteFaz 3
- Sarah Cannon Research Institute, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology, Nashville
- Tennessee Oncology, PLLC - Saint Thomas West, Nashville
- ak 3 plis
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Sarah Cannon Research Institute, Nashville
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, Nashville
- Research Site, Nashville
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- Tennessee Oncology, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- Tennessee Oncology, PLLC, Nashville
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Tennessee Oncology, Nashville
- USO - US Oncology Research Network, Nashville
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Ap rekriteFaz 1
- Xencor Investigative Site, Nashville
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- Tennessee Oncology, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Ap rekriteFaz 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
Ap rekriteEtid obsèvasyon
- Vanderbilt-Ingram Cancer Center, Nashville
- Veterans Affairs Medical Center - Nashville, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
Ap rekriteFaz 4
- Vanderbilt University/Ingram Cancer Center, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute (SCRI), Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Tennessee Oncology, Nashville
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Ap rekriteFaz 1/2
- Vanderbilt University/Ingram Cancer Center, Nashville
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
Ap rekriteFaz 1/2
- Vanderbilt University/Ingram Cancer Center, Nashville
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Arlington, VA41 etid
- Washington, DC41 etid
- Chicago, IL41 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
- Seattle, WA33 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
- Myelom Miltip32 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.